Literature DB >> 28692741

Pulmonary embolism in a morbidly obese patient receiving dabigatran.

Usama Nasir1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28692741      PMCID: PMC6490558          DOI: 10.1002/clc.22755

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


× No keyword cloud information.
  5 in total

1.  Ischemic stroke in an obese patient receiving dabigatran.

Authors:  Lorenz Breuer; Jürgen Ringwald; Stefan Schwab; Martin Köhrmann
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

2.  Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.

Authors:  K-H Liesenfeld; T Lehr; C Dansirikul; P A Reilly; S J Connolly; M D Ezekowitz; S Yusuf; L Wallentin; S Haertter; A Staab
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

3.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

Review 4.  The use of anticoagulants in morbidly obese patients.

Authors:  Justyna Domienik-Karłowicz; Piotr Pruszczyk
Journal:  Cardiol J       Date:  2015-09-28       Impact factor: 2.737

5.  Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report.

Authors:  James Rankin; Menachem Nagar; Jonathan Crosby; Nojan Toomari; Richard Pietras; Uri M Ben-Zur
Journal:  J Med Case Rep       Date:  2016-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.